Pharmafile Logo

What Is the RDI-Lancet Commission for Rare Disease and What Will It Achieve?

December 23, 2025 |  

Christy Rohani-Montez, Medscape’s Rare Disease Education Lead recently spoke with Dr Lucy McKay, CEO, and Megan Pullein, Strategic Operations Officer from the UK-based charity Medics for Rare Disease (MfRD). We discussed their involvement in the recently formed RDI-Lancet Commission for Rare Diseases, a global initiative aimed at developing evidence-based recommendations to improve the lives of the 400 million people living with rare diseases worldwide.

lucy                           Picture1megan

Lucy McKay                                                  Megan Pullein
CEO                                                                Strategic Operations Officer
Medics for Rare Disease                            Medics for Rare Disease

Christy: It’s lovely to be speaking with one of our favourite partners in rare disease, Medics for Rare Disease! Lucy, and Megan, could you start by introducing yourselves, Medics for Rare Disease, and its mission?

Lucy: Absolutely, I’m Dr Lucy McKay, the CEO of Medics for Rare Disease, and our vision is simple: equitable healthcare for everyone. Our mission is to shape a medical profession that can provide timely diagnosis and excellent care to people living with rare diseases.

Megan: I’m Megan Pullein, and I’m the Strategic Operations Officer at Medics for Rare Disease. My primary role is to help manage our work with the RDI-Lancet Commission, specifically for Working Group 2, which Lucy Co-Chairs.

Christy: What are the Lancet Commissions, and what is the RDI-Lancet Commission for Rare Diseases?

Megan: The Lancet Commissions are in-depth research initiatives that tackle urgent and complex global health issues. They gather experts from around the world to collaborate on solutions, which are then published in the renowned medical journal. The vision for this specific commission is to make rare diseases visible globally, ensuring that every person is seen, heard, and cared for, no matter where they live. The goal is to produce actionable recommendations that any government can take and implement within their society.

Christy: I understand that the commission is divided into 5 working groups. What is the focus of each?

Lucy: Before breaking down the groups, it’s important to state the golden thread that runs through all of this: human rights. The entire commission is fundamentally about achieving equity for patients around the world.

Megan: That leads perfectly into Working Group 1, which is focused on visibility for human rights. This is the core of the commission. Working Group 2, which we are leading, focuses on visibility for social justice. These are the 2 overarching themes. The other groups are more specific: Group 3 is looking at data and metrics; Group 4 is tackling visibility within healthcare systems, particularly the diagnostic odyssey; and Group 5 is focused on clinical pathways and trials.

Christy: Where does the work for each group start, and where does it end?

Lucy: We’re working in 3 phases. For example, in Working Group 2, first is a comprehensive literature review to answer the question: is social justice being achieved for people living with rare disease? If so, how? And if not, why not?

The second phase is generating new evidence. We want to fill the gaps we find in the literature, especially from geographical and demographical sources that are currently missing. We have a lofty goal of trying to represent advocates from every UN-recognized country, starting with the places from which we hear no voices.

The final phase will be to consolidate this evidence into concrete recommendations.

Christy: What do you find most exciting about RDI-Lancet Commission?

Lucy: For The Lancet to even highlight Rare Disease is a major milestone in history. What excites me is that this project forces us to pull back to focus on the individual. We constantly have to ask, for example, How is this recommendation going to help someone in rural Chile? It moves the conversation beyond tech, molecules, and industry chatter. Tech doesn’t matter to people if they can’t access it or are being treated without the respect every human being deserves.

It allows us to establish a global standard of provision for the rare disease community and will help shape The World Health Organisation’s Global Action Plan for Rare Disease. We hope that in the future there will be greater standardisation and transparency in how nations care for rare diseases. This will empower the rare disease community to understand what they are entitled to, the barriers to access and to demand accountability.

Christy: Thank you so much Lucy and Megan, it’s exciting to see this research moving forward, and we’re all looking forward to seeing the forthcoming publications.

For more information on the RDI-Lancet Commission:
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00211-9/abstract

About Medscape Education

Medscape Education (medscape.org) is the leading destination for continuous professional development, consisting of more than 30 specialty-focused destinations offering thousands of free CME and CE courses for physicians, nurses, and other healthcare professional

This content was provided by Medscape Education

Company Details

 Latest Content from  Medscape Education 

A Call to Action: Bridging the Adult Immunization Divide

Over the past few years, as new diseases have emerged or reemerged, a host of new vaccines have become available while many others are in the pipeline. For older adults,...

Medscape Education Returns as Thought Leaders to AIS 2025

📍 September 8–10, 2025 Hilton at Penn’s Landing | Philadelphia, PA Medscape Education is proud to return to the 2025 Alliance Industry Summit (AIS) as a Silver Sponsor and leading...

What Do Pickleball and Medscape Education Have in Common? Heather Lavigne.

When she’s not taking on challengers on the pickleball court, you can find Heather Lavigne leading Medscape Education’s dynamic insights and impact team as Senior Director. Her leadership philosophy is...

Medscape Education: Celebrating the Power, Purpose, and Future of Women in Medicine

Medscape Education is proud to return to the Power of Women in Medicine Summit™, reaffirming its commitment to uplifting, empowering, and amplifying women across healthcare. As a sponsor, Medscape brings...

Medscape Cardiology: Leading the Future of Heart Failure Education at HFSA 2025

Medscape Cardiology | theheart.org is proud to be at the forefront of the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM), September 26–29, 2025, in Minneapolis, MN! With...

Medical Misinformation and Sensationalism in the Age of Social Media

In today’s digital age, misinformation spreads faster than ever, often driven by sensational headlines and influencer content. These sources of misinformation often overshadow evidence-based content, creating confusion for both healthcare...

Medscape To Bring Leading Cardiology Education to ESC

The Medscape Global team is bringing their leading cardiology education and proven impact to the European Society of Cardiology (ESC) Congress in Madrid for 2025. Powered by enhanced technologies, methodologies,...

The Mission to Humanize Healthcare

Medical and scientific innovation are in a fast lane closely pursued by digital advances but their dynamism can mute a vital element of progressive healthcare – patient integration.

Medscape Education Wins SILVER for Rare Disease Campaign

We are thrilled to announce that Medscape Education has been honored with the SILVER Award in the Patient Education Information division category by the 2025 National Health Information Awards! This...

Honoring the Legacy of Dr. Robert Sidbury, MD, MPH

We are deeply saddened by the recent passing of Dr. Robert Sidbury. Dr. Sidbury was a visionary in pediatric dermatology whose dedication to advancing patient care inspired clinicians, researchers, and...